High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin |(Mylotarg®) treatment in acute myeloid leukemia patients

Leukemia

Volumn 18, Issue 5, 2004, Pages 983-988

  van der Velden, V H J ^a   Boeckx, N ^b   Jedema, I ^c   te Marvelde, J G ^a   Hoogeveen, P G ^a   Boogaerts, M ^b   van Dongen, J J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukemia; CD33 saturation; CD33 antigen load; Efficacy; Gemtuzumab ozogamicin

Indexed keywords

CD33 ANTIGEN; GEMTUZUMAB OZOGAMICIN; AMINOGLYCOSIDE; DIFFERENTIATION ANTIGEN; GEMTUZUMAB; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BONE MARROW; CANCER PATIENT; CANCER RECURRENCE; CELL KILLING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BINDING; DRUG EFFICACY; DRUG INFUSION; DRUG PENETRATION; HUMAN; IN VITRO STUDY; INTERNALIZATION; LEUKEMIA CELL; LEUKEMIA REMISSION; LIVER VEIN OBSTRUCTION; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; BLOOD;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; PROGNOSIS;

EID: 2342572260     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403350     Document Type: Article

References (18)

1. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R etal. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 2002; 13: 47-58.
2. Larson RA, Boogaerts M, Estey E, Karanes C, Stadtmauer EA, Sievers EL et al. Anti body-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002; 16: 1627-1636.
3. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244-3254.
4. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001; 92: 406-413.
5. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7: 1490-1496.
6. van der Velden VHJ, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97: 3197-3204.
7. Jedema I, Barge RMY, van der Velden VHJ, Nijmeijer BA, te Marvelde JG, van Dongen JJM et al. Internalization and cell cycle dependent killing of leukemic cells by gemtuzumab ozogamicin (GO): rationale for application in CD33 negative malignancies with endocytic capacity. Leukemia 2004; 18: 316-325.
8. Jedema I, Barge RM, Willemze R, Falkenburg JH. High susceptibility of human leukemic cells to Fas-induced apoptosis is restricted to G(1) phase of the cell cycle and can be increased by interferon treatment. Leukemia 2003; 17: 576-584.
9. van der Velden VHJ, Berger MS, van Dongen JJM. Mylotarg therapy in acute myeloid leukemia: mechanism of action and implications for future treatment protocols. Haematol Blood Transfusion 2003; 41: 169-176.
10. Giles F, Estey E, O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer 2003; 98: 2095-2104.
11. Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S et al. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 2003; 51: 87-90.
12. Kell WJ, Burnett AK, Chopra R, Yin JA, Clark RE, Rohatiner A et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003; 102: 4277-4283.
13. Tsimberidou A, Cortes J, Thomas D, Garcia-Manero G, Verstovsek S, Faderl S et al. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 2003; 27: 893-897.
14. Tsimberidou A, Estey E, Cortes J, Thomas D, Faderl S, Verstovsek S et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 2003; 97: 1481-1487.
15. Apostolidou E, Cortes J, Tsimberidou A, Estey E, Kantarjian H, Giles FJ. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res 2003; 27: 887-891.
16. Tsimberidou AM, Estey E, Cortes JE, Garcia-Manero G, Faderl S, Verstovsek S et al. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 2003; 52: 449-452.
17. Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley TA, Bennett JM et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001; 98: 988-994.
18. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML. Multidrug resistance protein attenuates gemtuzumab ozogamicin-incluced cytotoxicity in acute myeloid leukemia cells. Blood 2003; 102: 1466-1473.